增强的BCAT1活性和BCAA代谢促进了癌症进展中的RhoC活性
Lin Qian1,2, Na Li1,2,3, Xiao-Chen Lu1,2
1Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; School of Basic Medical Sciences; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; Shanghai Key Laboratory of Radiation Oncology; The Shanghai Key Laboratory of Medical Epigenetics, Shanghai Medical College, Fudan University, Shanghai, China.
Nature metabolism
|June 19, 2023
概括
分支链氨基酸转氨酶1 (BCAT1) 的特定突变通过促进氨基酸代谢和RhoC活性来增强癌细胞的生长和运动性. 坎德沙坦抑制了这种突变的BCAT1,为胃癌提供了潜在的治疗策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 分支链氨基酸转胺酶1 (BCAT1) 和BCAT2的表达增加与侵袭性癌症表型有关.
- 胃癌的进展涉及复杂的分子变化,影响细胞代谢和运动.
研究的目的:
- 为了研究在胃癌中发现的特定BCAT1突变 (BCAT1E61A) 的功能作用.
- 阐明BCAT1E61A影响癌细胞行为和瘤发育的机制.
- 为了确定BCAT1E61A驱动癌症的潜在治疗点.
主要方法:
- 对BCAT1E61A丰富的临床胃癌样本的分析.
- 生物化学测试以确定BCAT1E61A的酶活性.
- 基于细胞的测试以评估细胞生长,运动和RhoC活性.
- 在体外和体内实验中使用BCAT1淘汰模型和candesartan治疗.
主要成果:
- BCAT1E61A表现出更高的酶活性,促进分支链氨基酸 (BCAA) 代谢,细胞生长和运动.
- BCAT1E61A直接与RhoC相互作用并激活RhoC,RhoC是细胞运动的一个关键调节器.
- 由BCAA衍生的代谢物直接结合并激活RhoC.
- 坎德沙坦抑制了BCAT1E61A,减少了RhoC活性,体外癌细胞运动性和体内腹转移.
结论:
- BCAT1E61A通过将BCAA代谢与RhoC激活联系起来,提高细胞运动性和增殖,推动癌症的进展.
- 向BCAT1E61A与甘地沙坦等抑制剂,为胃癌提供了一个有前途的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K
The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


